Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 314

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 314
---
 Diego (UCSD); Tri-State Rett Syndrome Center at Montefiore Medical Center, Albert Einstein College of Medicine; and New York
Blood Center, Inc.

These organizations have provided,
and may continue to provide, DiamiR with plasma samples, and accompanying clinical data as available, including disease status, patient
demographics, neuroimaging data, CSF biomarkers analysis, cognitive assessment parameters, and accompanying diseases outcomes. DiamiR
works, and will continue to work, closely with the researchers and physicians at the centers to ensure that the available clinical data
is properly interpreted.

<div align='center'>179</div>

Intellectual Property

DiamiR relies on proprietary
technologies and product branding. Its policy is to seek patent protection domestically and internationally and trademark registration
for valuable assets, as appropriate, and maintain other aspects of its proprietary platform, processes, and know-how as trade secrets.

In February 2014 the United States
Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,648,017, entitled “Methods of using small RNA from bodily fluids
for diagnosis and monitoring of neurodegenerative diseases.” The patent, which is set to expire in November 2030, claims the
use of methods developed by DiamiR for early detection and diagnosis of neurodegenerative diseases (NDs).

In total, DiamiR has seven
families of issued patents.

The table below contains the
patent listing and country of issue for all of DiamiR’s 52 issued patents. DiamiR has an obligation to pay annual fees to keep these
patents active in the different territories that have issued the patents.

<div align='center'>Current DiamiR Patents Issued or Allowed</div>

Intellectual Property

The following provides a general
description of DiamiR’s patent portfolio and is not intended to represent an assessment of claim limitations or claim scope. Included
in the portfolio are seven (7) patent families.

On February 11, 2014,
the United States Patent and Trademark Office (“USPTO”) issued to DiamiR U.S. Patent No. 8,648,017, entitled “Methods
of Using Small RNA from Bodily Fluids for Diagnosis and Monitoring of Neurodegenerative Diseases.” The patent, which is set to expire
on November 4, 2030, claims the use of methods developed by DiamiR for detecting neurite destruction and synapse